VIEW SELECTED LIBRARY MEDIA

Original_edited.jpg

Name of Media:

Respiratory syncytial virus immune globulin: decisions and costs

Author(s):

University of York- the Centre for Reviews and Dissemination

Publisher or Source:

NHS Economic Evaluation Database - NHS EED

Type of Media:

Medical Professional Education

Media Originally for:

Critical Care Physicians

Country of Origin:

United Kingdom of Great Britain and Northern Ireland (the)

Primary Focus of Media:

Pre-Use of PICS Designation

COVID-19 Related:

No

Description:

Record Status

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Health technology

The use of prophylactic treatment with respiratory syncytial virus immune globulin (RSVIG) in paediatric patients at risk of developing RSV bronchiolitis and in paediatric patients at risk of developing a respiratory illness that would require hospitalisation. The use of RSVIG was compared with no prophylaxis. RSVIG was administered intravenously (IV) by home-based infusions (dose 750 mg/kg monthly) during the RSV season (November to April).

To view the attached Video media file, Click Icon:

PostICU, Inc's library staff reviewed this copyrighted material contained in the library and reasonably believes that its inclusion in our library complies with the "Fair Use Doctrine" because: (1) our library's is for nonprofit and educational purposes; (2) the nature of the copyrighted work is related to our mission; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole is fair and reasonable; and (4) the potential market for or value of the copyrighted work will if impacted, should be enhanced, by its presence in our library.